کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1392311 | 1501131 | 2014 | 11 صفحه PDF | دانلود رایگان |

• Aryl-N3-benzazepine framework is the prototypical dopamine D1 receptor ligand.
• Our study directly focused on modification of the metabolic site-catechol moiety.
• Compounds 13b–d displayed Ki values of 270–370 nM at the D1 receptor.
• Most compounds possess high affinity less than 10 nM at the 5-HT2A receptor.
• 13a was the most potent with a Ki value of 4.5 nM at the 5-HT2A receptor.
A series of new benzazepines with modification on the catecholic fragment were designed. The 8-hydroxyl group, other than the 7-hydroxyl was confirmed crucial to the interaction with the dopamine D1 receptor. Subsequent replacement of the 7-hydroxyl with benzylamino groups was found tolerable. 7-(m-Chlorophenyl)methylamino- and 7-(m- or o-tolyl)methylamino-substituted benzazepines 13b–d displayed Ki values of 270–370 nM at the D1 receptor, which were slightly more potent than that of parent compound 1. In addition, 7-(arylmethyl)amino-benzazepines 13a–c were found possessing high binding affinities less than 10 nM at the 5-HT2A receptor. Among them, the non-substituted 7-benzylamino analogue 13a was the most potent showing a Ki values of 4.5 nM at the 5-HT2A receptor and a 5-HT2A/D1 selectivity of 147.
Figure optionsDownload as PowerPoint slide
Journal: European Journal of Medicinal Chemistry - Volume 85, 6 October 2014, Pages 16–26